What is Alembic Pharmaceuticals Limited (APLLTD) share price today?

Alembic Pharmaceuticals Limited (APLLTD) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/APLLTD for the latest live price, technical analysis, and AI-powered insights.

How to analyse APLLTD stock?

VestAI provides comprehensive APLLTD stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Alembic Pharmaceuticals Limited in?

Alembic Pharmaceuticals Limited (APLLTD) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Alembic Pharmaceuticals Limited

Name: Alembic Pharmaceuticals Limited (APLLTD) Financial Metrics
Creator: VestAI
License: https://www.vestai.io/terms

APLLTD

NSE· Healthcare

₹816.70

+2.25 (+0.28%)

52W Low · ₹635.8052W High · ₹1,026.20

Mid Range

Market Cap

₹15677.87L Cr

Volume

63.2K

Prev Close

₹797.60

ISIN

INE901L01018

Orion Score

Fundamentals-based quality & risk · not a recommendation

59/100

Watch

Alembic Pharmaceuticals Limited scores 59/100 (Watch) on the Orion Score — moderate business quality (58), moderate growth (57), strong balance-sheet safety (71) and fair valuation (47). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Profit converts to cash (CFO 1.1× PAT)
Low debt, comfortable interest cover
No distress, manipulation or dilution flags

Forensic accounting

Piotroski F 5/9Altman Z Safe(7.82)Beneish M Clean(-2.52)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

45/100

Neutral

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.25x — lean balance sheet

QUALITY

Average

ROCE 13.0% — decent returns

MOMENTUM

Neutral

RSI 52.3 — consolidating

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio: 23.23
ROCE: 13.03%
ROE (1Y): 12.36%
D/E Ratio: 0.25x
OPM: 7.54%
TTM EPS: ₹34.33
Dividend Yield: 150.00%
Qtrly Sales: ₹1,847.72 Cr
Qtrly Profit: ₹202.70 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q4 2026	₹1,847.72	₹202.7	7.5%	₹10.31
Q3 2026	₹1,876.31	₹132.97	11.4%	₹6.76
Q1 2026	₹1,710.72	₹154.38	12.1%	₹7.85
Q4 2025	₹1,769.64	₹156.89	11.5%	₹7.98
Q3 2025	₹1,692.74	₹138.42	11.2%	₹7.01

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2025	₹6,539.71	₹583.42	₹1,064.53	11.2%
FY 2024	₹6,112.11	₹615.82	₹960.69	10.9%
FY 2023	₹5,499.77	₹341.99	₹680.19	8.1%
FY 2022	₹5,231.79	₹520.94	₹929.9	11.3%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
APLLTD ★	₹15,678 Cr	23.23	13.03%	12.36%	0.25x	7.54%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
CIPLACipla Limited	₹1,13,955 Cr	33.87	13.66%	11.74%	0.02x	12.55%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹88,148 Cr	25.39	12.55%	9.93%	0.21x	15.11%
ASTERDMAster DM Quality	₹68,390 Cr	104.34	8.93%	10.07%	0.46x	13.98%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹7,772.94	₹6,445.58	₹6,182.83	₹7,122.03
Equity	₹5,190.94	₹4,818.2	₹4,370.46	₹5,237.55
Total Debt	₹1,257.5	₹513.16	₹722.01	₹717.11
Cash	₹83.48	₹120.21	₹75.48	₹61.09
Net Debt	₹1,112.09	₹310.24	₹560.38	₹568.9
Working Capital	₹1,675.45	₹1,623.56	₹1,273.1	₹1,144.26

Shareholding Pattern

Q1 FY2027

Promoter

70.64%

FII

9.28%

DII

7.6%

Public

12.48%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	70.64% ↑	9.28% ↓	7.6% ↓	12.48% ↑
Q4 FY2026	70.56% ↑	9.34% ↑	7.65% ↓	12.45% ↑
Q3 FY2026	69.74%	4.23% ↑	16.17% ↓	9.84% ↓
Q2 FY2026	69.74% ↑	4.04% ↑	16.3% ↓	9.92%
Q1 FY2026	69.68% ↑	3.96% ↑	16.46% ↑	9.91% ↓
Q4 FY2025	69.67% ↑	3.94% ↓	16.43% ↑	9.96% ↓
Q3 FY2025	69.61%	4.17% ↑	16.05%	10.17% ↓
Q2 FY2025	69.61%	3.94%	16.05%	10.38%

Corporate Actions

Ex-Date	Action	Details
2026-07-29	DIVIDEND	Dividend - Rs 12 Per Share

Funds Holding This Stock

35 mutual fund schemes

DSP Healthcare Fund Direct GrowthDSP

3.21%

₹106 Cr

ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct GrowthICICI_PRUDENTIAL

1.76%

₹113 Cr

Kotak Small Cap Fund Direct GrowthKOTAK_MAHINDRA

1.42%

₹253 Cr

Abakkus Small Cap Fund Direct GrowthAbakkus

1.35%

₹15 Cr

Aditya Birla Sun Life Pharma & Healthcare Fund Direct GrowthBIRLA_SUN_LIFE

1.25%

₹12 Cr

UTI Healthcare Fund Direct GrowthUTI

1.02%

₹13 Cr

WSIF Equity Long Short Fund Direct GrowthWSIF

0.88%

—

DSP Midcap Direct Plan GrowthDSP

0.79%

₹155 Cr

WSIF Equity Ex Top 100 Long Short Fund Direct GrowthWSIF

0.79%

—

DSP ELSS Tax Saver Fund Direct Plan GrowthDSP

0.65%

₹105 Cr

Analyse APLLTD with Orion AI

Ask: "Is Alembic Pharmaceuticals Limited stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Alembic Pharmaceuticals Limited (APLLTD) Stock

Alembic Pharmaceuticals Limited is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE901L01018. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.